CEL-SCI Corporation

Impact: CEL-SCI Corporation closed a public offering of 6,000,000 shares of its common stock, raising approximately $7.2 million in gross proceeds to fund the continued development of Multikine, general corporate purposes, and working capital.

Impact: CEL-SCI Corporation announced the pricing and closing of a public offering of its common stock, raising $2.5 million in gross proceeds. This funding is intended to support the continued development of Multikine, general corporate purposes, and working capital.

Impact: CEL-SCI Corporation has entered into a strategic agreement with Saudi Amarox for the commercialization and distribution of its cancer immunotherapy, Multikine, in Saudi Arabia, which is a significant step towards expanding its market reach and potential revenue.

Impact: CEL-SCI Corporation is the developer of Multikine and the sponsor of the Phase 3 trial. The publication validates its clinical data and supports its upcoming Confirmatory Registration Study, potentially enhancing its market position and stock value.